Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials

Qianqian Xin, Qianhui Wu, Xinhua Chen, Bihua Han, Kai Chu, Yan Song, Hui Jin, Panpan Chen, Wanying Lu, Tuantuan Yang, Minjie Li (), Yuliang Zhao (), Hongxing Pan (), Hongjie Yu () and Lin Wang ()
Additional contact information
Qianqian Xin: Sinovac Biotech
Qianhui Wu: Fudan University, Key Laboratory of Public Health Safety, Ministry of Education
Xinhua Chen: Fudan University, Key Laboratory of Public Health Safety, Ministry of Education
Bihua Han: Hebei Provincial Center for Disease Control and Prevention
Kai Chu: Jiangsu Provincial Center for Disease Control and Prevention
Yan Song: Suining County Center for Disease Control and Prevention
Hui Jin: Renqiu Center for Disease Control and Prevention
Panpan Chen: Renqiu Center for Disease Control and Prevention
Wanying Lu: Fudan University, Key Laboratory of Public Health Safety, Ministry of Education
Tuantuan Yang: Sinovac Biotech
Minjie Li: Hebei Provincial Center for Disease Control and Prevention
Yuliang Zhao: Hebei Provincial Center for Disease Control and Prevention
Hongxing Pan: Jiangsu Provincial Center for Disease Control and Prevention
Hongjie Yu: Fudan University, Key Laboratory of Public Health Safety, Ministry of Education
Lin Wang: Sinovac Life Sciences

Nature Communications, 2022, vol. 13, issue 1, 1-7

Abstract: Abstract Determining the duration of immunity induced by booster doses of CoronaVac is crucial for informing recommendations for booster regimens and adjusting immunization strategies. In two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, immunogenicity and safety of four immunization regimens are assessed in adults aged 18 to 59 years and one immunization regimen in adults aged 60 years and older, respectively. Serious adverse events occurring within 6 months after booster doses are recorded as pre-specified secondary endpoints, geometric mean titres (GMTs) of neutralising antibodies one year after the 3-dose schedule immunization and 6 months after the booster doses are assessed as pre-specified exploratory endpoints, GMT fold-decreases in neutralization titres are assessed as post-hoc analyses. Neutralising antibody titres decline approximately 4-fold and 2.5-fold from day 28 to day 180 after third doses in adults aged 18–59 years of age and in adults aged 60 years and older, respectively. No safety concerns are identified during the follow-up period. There are increases in the magnitude and duration of humoral response with homologous booster doses of CoronaVac given 8 months after a primary two-dose immunization series, which could prolong protection and contribute to building our wall of population immunity. Trial number: NCT04352608 and NCT04383574.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30864-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30864-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30864-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().